Now showing items 1-10 of 22
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
(The Cochrane Collaboration., 2013)
The primary objective of this review was to evaluate the antiviral efficacy of co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection. The secondary objectives were to evaluate the safety and ...
The abandoned trials of pre-exposure prophylaxis for HIV : what went wrong?
Discusses the impact of irresponsible reporting and activism against the use of the oral antiretroviral drug tenofovir as a pre-exposure prophylaxis (PREP) for HIV/AIDS. Protests against trials of PREP; Concerns of the ...
Antiretroviral prophylaxis for HIV prevention reaches a key milestone.
No abstract available.
Balancing efficiency, equity and feasibility of HIV treatment in South Africa – development of programmatic guidance.
(BioMed Central., 2013)
South Africa, the country with the largest HIV epidemic worldwide, has been scaling up treatment since 2003 and is rapidly expanding its eligibility criteria. The HIV treatment programme has achieved significant results, ...
A pilot study of once-daily antiretroviral therapy integrated with Tuberculosis directly observed therapy in a resource-limited setting.
(Lippincott Williams & Wilkins., 2003)
To determine the feasibility and effectiveness of integrating highly active antiretroviral therapy (HAART) into existing tuberculosis directly observed therapy (TB/DOT) programs, we performed a pilot study in an urban ...
Patients’ readiness to start highly active antiretroviral treatment for HIV.
(BMJ publishing group., 2005)
Assessing whether patients are ready to start antiretroviral treatment may improve HIV prevention and treatment outcomes.
An adaptive design to bridge the gap between phase 2b/3 microbicide effectiveness trials and evidence required for licensure.
Background. Vaginally and rectally applied microbicides are being developed to help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the path toward licensure typically moves directly from expanded ...
Innate immune activation enhances HIV acquisition in women, diminishing the effectiveness of tenofovir microbicide gel.
(Oxford University Press., 2011)
The antiretroviral agent, tenofovir, formulated as a vaginal microbicide gel, reduces human immunodeficiency virus (HIV) acquisition by 39% in women. This study assessed the role of preexisting immune activation in ...
Topical microbicides - What's new?
(Lippincott Williams & Wilkins., 2013)
Topical microbicides are an important, promising but complex HIV prevention technology under development. After 11 disappointing effectiveness trial outcomes of 6 candidate products (some tested as multiple doses and ...
An AIDS-Free Generation?
(American Association for the Advancement of Science., 2012)
No abstract available.